Publications by authors named "Matt Burge"
Article Synopsis
- Gastrointestinal stromal tumours (GISTs) are the most common type of mesenchymal tumours in the gastrointestinal tract, and the advent of tyrosine kinase inhibitors (TKIs) has significantly improved treatment options for advanced cases.
- Imatinib was the first TKI approved for advanced GIST, setting a new standard of care, and now there are five approved targeted therapies available, including sunitinib and regorafenib, following key clinical trials like GRID and INVICTUS.
- The Australasian Gastrointestinal Trials Group (AGITG) highlights the importance of molecular testing to guide therapy based on specific molecular targets, as well as future directions for treating advanced GISTs.
Introduction: Pancreatic cancer remains a challenging malignancy due to the high proportion of patients diagnosed at advanced stages and the limited treatment options. This article discusses recent evidence in the management of both localized and advanced pancreatic cancer and offers an expert opinion on current best practice.
Areas Covered: For patients with localized disease, the evidence for adjuvant chemotherapy is discussed as well as emerging neoadjuvant approaches for resectable, borderline resectable, and locally advanced disease.
Article Synopsis
- A multimodal approach to treating early-stage oesophago-gastric (OG) cancer has significantly improved patient outcomes over the past decade, as highlighted in a review of current literature and conference presentations.
- This review emphasizes the importance of adjunctive therapies, such as neoadjuvant and perioperative chemotherapy or chemoradiotherapy, which outperform surgery alone in enhancing survival rates for patients.
- The article also discusses the potential of immunotherapy, targeted drugs, and advances in molecular biology to address the challenges of tumor heterogeneity and to develop more effective, individualized treatments.
Background: The use of bevacizumab in combination with fluoropyrimidine-containing chemotherapy is a well-established first-line and second-line treatment for patients with metastatic colorectal cancer (mCRC). However, there remains a need for reproducible, validated, inexpensive and accessible prognostic markers to aid treatment selection. The optimal treatment duration and the role of bevacizumab in certain patient subgroups, considered at particular risk of bevacizumab-mediated toxicity, also require further investigation.
View Article and Find Full Text PDF